
    
      This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in
      healthy adults above 18 years of age,inclusive, who meet all eligibility criteria. This
      clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which
      encodes for a full-length spike (S) protein of SARS-CoV-2. 500 subjects will be enrolled, 250
      subjects in middle-dose vaccine group, 125 subjects in low-dose and placebo group,
      respectively. Immunogenicity will be tested on days 0, 14, 28 and 6 months after vaccination
    
  